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Dear Editor, 
 
Diosgenin, a phytosteroid saponin, is found at high levels in several plant species, including 
Costus speciosus, Smilax menispermoidea, Trigonella foenum, species of Paris, Aletris, 
Trigonella, and Trillium, and many species of Dioscorea (Patel et al., 2013; Chen et al., 2011). 
Fujii and Matsukawa first discovered diosgenin within Dioscorea tokoro Makino in 1935 
(Djerassi et al., 1952). The biosynthesis of steroidal saponins such as diosgenin in plants has 
not yet been reported in detail, although cholesterol was found to be a precursor of this com-
pound. Cholesterol is formed from lanosterol and some of the reactions involved are catalyzed 
by cytochrome P450 systems. Vaidya et al. (2013) suggested that diosgenin might be formed 
from squalene-2,3-oxide in two ways: from lanosterol via cholesterol, and from cycloartenol 
via the formation of sitosterol (Ciura et al., 2017). 
In the pharmaceutical industry, diosgenin is the principal precursor compound in the man-
ufacture of several synthetic steroidal drugs (Chen et al., 2015). It also represents a promising 
bioactive biomolecule that exhibits various biological properties; these include hypolipidemic, 
hypoglycemic, antioxidant, anti-inflammatory, and antiproliferative activities (Jesus et al., 
2016). Diosgenin has therefore attracted considerable attention in recent years within the phar-
maceutical, functional food, and cosmetic industries. Here, we summarize recent studies per-
formed to evaluate the biological and pharmacological activities of diosgenin (Table 1).  
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Table 1: Recent studies of the biological and pharmacological activities of diosgenin 
Key findings Reference 
Diosgenin selectively suppressed the production/expression of pro-in-
flammatory M1 markers by activated microglia, without affecting M2 
markers, and might provide neuroprotection by regulating microglial M1 
polarization. 
Wang et al., 2017 
Diosgenin inhibited resilient breast cancer stem cells. This could provide 
a rationale for the development of diosgenin-based therapies for breast 
cancer. 
Bhuvanalakshmi 
et al., 2017 
 
Diosgenin inhibited angiotensin II-induced extracellular matrix remodeling 
in rat cardiac fibroblasts by suppressing the transforming growth factor-
β1/Smad3 signaling pathway. Diosgenin may therefore possess thera-
peutic potential for the treatment of cardiac fibrosis. 
Zhou et al., 2017 
Diosgenin improved skin collagen levels by shifting the fibroblast dynam-
ics from proliferation to differentiation via cell cycle arrest. 
Haratake A et al., 
2017 
Diosgenin played a protective role against osteoarthritis by activating the 
sirtuin type 1 signaling pathway, inhibiting chondrocyte apoptosis, and in-
creasing chondrocyte mitochondrial oxidative stress capacity. 
Liu et al., 2017 
High glucose-induced myocardial injury was prevented using morroniside 
and/or diosgenin, which reduced oxidative stress and apoptosis in rat car-
diomyocytes. Morroniside plus diosgenin produced a stronger effect than 
either compound alone. 
Pi et al., 2017 
Diosgenin suppressed the secretion of tumor necrosis factor-α, interleu-
kin-1β, and interleukin-6, enhanced the expression of glucocorticoid re-
ceptors, SLPI (secretory leukocyte protease inhibitor), GILZ (glucocorti-
coid-induced leucine zipper), and MKP-1 (mitogen-activated protein ki-
nase phosphatase-1), and inhibited the expression of HSP70. These find-
ings could provide some valuable information on the molecular mecha-
nism underlying the effects of diosgenin, which might facilitate its clinical 
application. 
Junchao et al., 
2017 
Administration of diosgenin to allergic mice greatly enhanced the induc-
tion of T helper 1-like regulatory T cells, suggesting a role for these cells 
in the anti-allergic effects of diosgenin against T helper 2-type allergies. 
Huang et al., 2017 
Structure-activity analyses indicated that diosgenin analogues with a sim-
ple phenyl R moiety or electron-withdrawing ortho-substituted R moieties 
showed improved anti-proliferative activities. 
Masood-Ur-Rah-
man et al., 2017 
The combination of diosgenin with an autophagy inhibitor may be an ef-
fective strategy to increase the antitumor effect of diosgenin. 
Nie et al., 2016 
Sterol regulatory element-binding transcription factor-1 appeared to be a 
major target of diosgenin and mediated its anti-diabetic activities in gesta-
tional diabetes. This information provided an insight into the biological ac-
tivities of diosgenin and will provide novel opportunities to investigate its 
anti-diabetic activities. 
Hua et al., 2016 
Diosgenin inhibited apoptosis and increased the mitochondrial oxidative 
stress capacity of chondrocytes in mice with osteoarthritis; this effect was 
closely related to Janus kinase 2/signal transducer and activator of tran-
scription 3 signaling pathway activation. 
Liu et al., 2016 
Diosgenin inhibited testosterone propionate-induced prostate enlarge-
ment and may be a candidate agent for the treatment of benign prostatic 
hyperplasia. 
Chen et al., 2016 
Diosgenin and 5-methoxypsoralen improved insulin resistance via an es-
trogen receptor-mediated phosphatidylinositol 3-kinase/Akt activation 
pathway. This might provide a new approach to the treatment of type 2 di-
abetes mellitus, especially for women with low estrogen levels. 
Fang et al., 2015 
 
Diosgenin enhanced eryptosis, shrinking erythrocytes and scrambling 
phospholipids in the erythrocyte cell membrane. This was associated with 
Ca2+ entry, oxidative stress, and ceramide. 
Mischitelli et al., 
2016 
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Key findings Reference 
Diosgenin was neuroprotective against ischemia-reperfusion-induced in-
jury. This effect involved anti-apoptotic and anti-inflammatory activity, and 
modulation of nuclear factor-κB signaling pathway properties.  
Zhang et al., 2016 
Compound 5, a new derivative of diosgenin, exhibited  antithrombotic ac-
tivity, mainly by reducing platelet aggregation and regulating factor VIII. 
This effect was comparable to that of aspirin, but with fewer side effects. 
Zheng et al., 2016 
Diosgenin increased compact bone formation and probably inhibited can-
cellous bone resorption, which led to an improvement of the mechanical 
properties of compact and cancellous bone. 
Folwarczna et al., 
2016 
Diosgenin treatment successfully suppressed phthalic anhydride-induced 
skin inflammation in interleukin-4/ luciferase/CNS-1 (the enhancer of in-
terleukin-4) transgenic mice by reducing expression of interleukins -4 and 
-6, and reducing the immunoglobulin E level and mast cell infiltration. 
Kim et al., 2016 
Diosgenin increased the generation of reactive oxygen species and this 
was cytotoxic to chronic myeloid leukemia cells, while also inducing au-
tophagy. Autophagy functions as a cytoprotective mechanism to reduce 
the cytotoxicity of diosgenin in tumor cells; inhibition of autophagy can 
thus enhance the anti-chronic myeloid leukemia activity of diosgenin. 
Jiang et al., 2016 
Diosgenin prevented bone loss in experimental rats by increasing the 
level of estradiol, reducing bone turnover. 
Zhao et al., 2016 
Diosgenin inhibited proliferation and activation of hepatic stellate cells-T6 
cells, at least in part, via the transforming growth factor-β1/Smad signal-
ing pathway. These results indicated that diosgenin may have the poten-
tial to treat liver fibrosis. 
Xie et al., 2015 
Diosgenin reduced age-associated changes in femur microarchitecture 
and morphology in senescence-accelerated OXYS rats, suggesting that 
diosgenin may have beneficial effects on aging-induced osteoporosis. 
Tikhonova et al., 
2015 
Diosgenin isolated from Costus speciosus showed anticancer and pro-
apoptotic effects on cancer cell proliferation. 
Selim and Al Ja-
ouni, 2015 
Diosgenin inhibited interleukin-1β-induced expression of inflammatory 
mediators, indicating that it could be used as a potential treatment for os-
teoarthritis. 
Wang et al., 2015 
Diosgenin modulated the opening of mitochondrial ATP-sensitive potas-
sium channels and reduced oxidative stress. These activities could con-
tribute to the cardioprotective effect of diosgenin in ischemia-reperfusion-
induced injury. 
Badalzadeh et al., 
2015 
Diosgenin enhanced ATP-binding cassette transporter of A1-dependent 
cholesterol efflux and prevented aortic atherosclerosis progression by re-
ducing the expression of macrophage miR-19b. 
Lv et al., 2015 
Hypercholesterolemia and hepatosteatosis were prevented by diosgenin-
mediated modulation of enzymes associated with cholesterol metabolism. 
Hao et al., 2015 
Diosgenin showed the potential to produce anti-diabetic effects that miti-
gated hyperglycemia and insulin resistance, as well as alleviating meta-
bolic dysregulation of the lipid profile in both plasma and tissues. 
Naidu et al., 2015 
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